DOCSLIB.ORG

Haematology: Non-Malignant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Haematology: Non-Malignant Haematology: Non-Malignant Mr En Lin Goh, BSc (Hons), MBBS (Dist.), MRCS 25th February 2021 Introduction • ICSM Class of 2018 • Distinction in Clinical Sciences • Pathology = 94% • Wallace Prize for Pathology • Jasmine Anadarajah Prize for Immunology • Abrahams Prize for Histopathology Content 1. Anaemia 2. Haemoglobinopathies 3. Haemostasis and thrombosis 4. Obstetric haematology 5. Transfusion medicine Anaemia Background • Hb <135 g/L in males and <115 g/L in females • Causes: decreased production, increased destruction, dilution • Classified based on MCV: microcytic (<80 fL), normocytic (80-100 fL), macrocytic (>100 fL) • Arise from disease processes affecting synthesis of haem, globin or porphyrin Microcytic anaemia work-up • Key differentials • Iron deficiency anaemia • Thalassaemia • Sideroblastic anaemia • Key investigations • Peripheral blood smear • Iron studies Iron deficiency anaemia • Commonest cause is blood loss • Key features • Peripheral blood smear – pencil cells • Iron studies – ↓iron, ↓ferritin, ↑transferrin, ↑TIBC • FBC – reactive thrombocytosis • Management – investigate underlying cause, iron supplementation Thalassaemia • α-thalassaemia, β-thalassaemia, thalassaemia trait • Key features • Peripheral blood smear – basophilic stippling, target cells • Iron studies – all normal • Management – iron supplementation, regular transfusions, iron chelation Sideroblastic anaemia • Congenital or acquired • Key features • Peripheral blood smear – basophilic stippling • Iron studies – ↑iron, ↑ferritin, ↓transferrin, ↓TIBC • Bone marrow – ringed sideroblasts • Management – treat underlying cause, regular transfusions Macrocytic anaemia work-up • Key differentials • Megaloblastic anaemia: vitamin B12 deficiency, folate deficiency • Alcohol • Hypothyroidism • Key investigations • Peripheral blood smear • LFTs • TFTs Megaloblastic anaemia • Vitamin B12 or folate deficiency • How to differentiate? • Duration – months for folate deficiency, years for vitamin B12 deficiency • Clinical findings – vitamin B12 deficiency associated with neurological changes • Serum methylmalonic acid – elevated in vitamin B12 deficiency • Schilling test – positive in vitamin B12 deficiency 2º to pernicious anaemia • Drug history – phenytoin inhibits folate absorption • Management – vitamin supplementation Non-megaloblastic anaemia • Alcohol, hypothyroidism, pregnancy • How to differentiate? • History – features of hypothyroidism • Clinical findings – hepatomegaly, gynaecomastia, abdominal veins, ascites, jaundice • LFTs – ↑AST, ↑ALT, ↑GGT, AST:ALT >2:1 • TFTs – ↑TSH, ↓T3/T4, anti-thyroid peroxidase antibodies • Management – treat underlying cause Normocytic anaemia work-up • Key differentials • Haemolytic: inherited or acquired (immune-mediated, non-immune-mediated) • Non-haemolytic: anaemia of chronic disease, failure of erythropoiesis • Key investigations • Peripheral blood smear • DAT • CRP, ESR Anaemia of chronic disease • Infection, inflammation, malignancy • Key features • Inflammatory markers – raised CRP, ESR • Iron studies – ↑iron, ↑ferritin, ↓transferrin, ↓TIBC • Management – treat underlying cause SBA 1 A 65-year-old lady presents with recent onset of fatigue and dyspnoea on exertion. She reports a decrease in appetite, constipation and weight gain. Her full blood count results show: Hb = 100 g/L, MCV = 102 fL. Which of the following is the likely diagnosis? a. Underlying malignancy b. Vitamin B12 deficiency c. Hypothyroidism d. Inflammatory bowel disease e. Liver disease SBA 1 A 65-year-old lady presents with recent onset of fatigue and dyspnoea on exertion. She reports a decrease in appetite, constipation and weight gain. Her full blood count results show: Hb = 100 g/L, MCV = 102 fL. Which of the following is the likely diagnosis? a. Underlying malignancy b. Vitamin B12 deficiency c. Hypothyroidism d. Inflammatory bowel disease e. Liver disease VSA 1 A 25-year-old lady presents with a 3-month history of worsening paraesthesia in her feet. She is a life-long vegetarian. Hb = 100 g/L, MCV = 110 fL. Which vitamin is she likely deficient in? VSA 1 A 25-year-old lady presents with a 3-month history of worsening paraesthesia in her feet. She is a life-long vegetarian. Hb = 100 g/L, MCV = 110 fL. Which vitamin is she likely deficient in? Vitamin B12 Haemolytic anaemia • Inherited or acquired (immune-mediated vs non-immune-mediated) • Inherited • Hereditary spherocytosis • Glucose-6-phosphate dehydrogenase deficiency • Immune • Autoimmune: warm vs cold haemolytic anaemia • Alloimmune: ABO or Rhesus incompatibility • Non-immune • Microangiopathic vs macroangiopathic • Infection Hereditary spherocytosis • Autosomal dominant • Defect in the vertical interaction of the red cell membrane • Key features • Peripheral blood smear: spherocytes, polychromasia • Positive osmotic fragility test • Positive eosin-5-maleimide (most sensitive test) • Management – folate supplementation, splenectomy G6PD • X-linked recessive • G6PD generates NADPH via pentose phosphate pathway • Key features • Episodes of acute haemolysis following exposure to oxidative stress (e.g. fava beans, mothballs, drugs) • Peripheral blood smear: Heinz bodies, bite cells • Intravascular haemolysis: ↑unconjugated bilirubin, ↓haptoglobin, haemoglobinuria • Management – avoidance of triggers, supportive care AIHA • Immune-mediated destruction of red blood cells, DAT positive • Warm • Mediated by IgG • Associated with CLL, SLE, methyldopa • Extravascular haemolysis • Cold • Mediated by IgM • Associated with Mycoplasma, EBV, hepatitis C • Intravascular haemolysis • Management – treat underlying cause, steroids, rituximab MAHA • Non-immune-mediated, small vessel disease • Damage to endothelial cells within the vasculature à fibrin deposition and platelet aggregation à fragmentation of red blood cells • Key features • Peripheral blood smear: schistocytes, thrombocytopenia • Disorders – HUS, TTP, DIC • Distinguish from DIC with normal APTT, PT, fibrinogen • Management – treat underlying cause, supportive HUS • Commonly caused by Escherichia coli O157:H7 – Shiga-like toxin • More frequent but less severe in children • Key features • Symptoms occur after a diarrhoeal illness – do not give antibiotics to treat • Triad of MAHA, thrombocytopenia, acute renal failure – self-limiting in children • Features of MAHA on peripheral blood smear • Management – supportive care TTP • Deficiency of ADAMTS13 à decreased break down of multimers of vWF • Can be inherited or acquired • Key features • Pentad of MAHA, thrombocytopenia, acute renal failure, neurological symptoms, fever • High mortality rate • Management – supportive care, plasma exchange SBA 2 A 6-month-old African boy presents with abdominal pain, jaundice and dark urine. He was diagnosed with a urinary tract infection three days ago and was started on nitrofurantoin. He has not experienced any similar episodes in the past. Which of the following is a likely diagnosis? a. Sickle cell anaemia b. Glucose-6-phosphate dehydrogenase deficiency c. Sepsis d. β-thalassaemia major e. Autoimmune haemolytic anaemia SBA 2 A 6-month-old African boy presents with abdominal pain, jaundice and dark urine. He was diagnosed with a urinary tract infection three days ago and was started on nitrofurantoin. He has not experienced any similar episodes in the past. Which of the following is a likely diagnosis? a. Sickle cell anaemia b. Glucose-6-phosphate dehydrogenase deficiency c. Sepsis d. β-thalassaemia major e. Autoimmune haemolytic anaemia VSA 2 An 83-year-old man with a diagnosis of chronic lymphocytic leukaemia presents with worsening tiredness, dyspnoea and reduced exercise tolerance. Hb = 66 g/L, DAT positive. What is the causative antibody underlying his condition? VSA 2 An 83-year-old man with a diagnosis of chronic lymphocytic leukaemia presents with worsening tiredness, dyspnoea and reduced exercise tolerance. Hb = 66 g/L, DAT positive. What is the causative antibody underlying his condition? IgG Haemoglobinopathies Background • Genetic disorders of globin chain synthesis • Haemoglobin • HbA (α2β2) – late foetus, infant, child and adult • HbA2 (α2δ2) – infant, child and adult • HbF (α2ɣ2) – foetus, infant • Diagnosis made with Hb electrophoresis • Disorders – thalassaemia, sickle cell disease β-thalassaemia Chr 11 β-globin • Reduced synthesis of β globin chain (Chromosome 11) β-globin • Major (homozygous), intermedia and minor (heterozygous) • Key features • Major – severe anaemia requiring regular blood transfusions • Intermedia – genetically complex, moderate reduction in β globin chain production • Minor – benign but important genetically • Management – regular blood transfusions, iron chelation, folate supplementation α-thalassaemia • Reduced synthesis of α globin chain (Chromosome 16) • Hb Barts (x4), HbH (x3), trait (x2), silent (x1) Chr 16 α-globin α-globin • Key features α-globin α-globin • Hb Barts – fatal in utero, hydrops foetalis • HbH – severe anaemia in childhood, hepatosplenomegaly • Trait – mild anaemia • Silent – asymptomatic • Management – regular blood transfusions, iron chelation, folate supplementation Sickle cell disease • Autosomal recessive • Glu à Val mutation at codon 6 on the β globin chain à HbS • HbSS, HbAS, HbSC, HbSβ • Key features • Haemolytic crisis, sequestration crisis, aplastic crisis, infection (Streptococcus pneumoniae – sepsis, Salmonella sp– osteomyelitis) • Peripheral blood smear: sickle cells • Sickle solubility test positive in HbSS and HbAS • Management – vaccination, folate supplementation, hydroxyurea,
Load more

Recommended publications
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • Autosomal Recessive Disorders and X Linked Disorders in Malaysia
    Patricia Bowen Library & Knowledge Service Email: [email protected] Website: http://www.library.wmuh.nhs.uk/wp/library/ DISCLAIMER: Results of database and or Internet searches are subject to the limitations of both the database(s) searched, and by your search request. It is the responsibility of the requestor to determine the accuracy, validity and interpretation of the results. Date: 27 January 2020 Sources Searched: Medline, Embase. Autosomal Recessive Disorders and X Linked Disorders in Malaysia See full search strategy 1. International perspectives on the implementation of reproductive carrier screening. Author(s): Delatycki, Martin B; Alkuraya, Fowzan; Archibald, Alison; Castellani, Carlo; Cornel, Martina; Grody, Wayne W; Henneman, Lidewij; Ioannides, Adonis S; Kirk, Edwin; Laing, Nigel; Lucassen, Anneke; Massie, John; Schuurmans, Juliette; Thong, Meow-Keong; van Langen, Irene; Zlotogora, Joël Source: Prenatal diagnosis; Nov 2019 Publication Date: Nov 2019 Publication Type(s): Journal Article Review PubMedID: 31774570 Available at Prenatal diagnosis - from Wiley Online Library Abstract:Reproductive carrier screening started in some countries in the 1970s for hemoglobinopathies and Tay-Sachs disease. Cystic fibrosis carrier screening became possible in the late 1980s and with technical advances, screening of an ever increasing number of genes has become possible. The goal of carrier screening is to inform people about their risk of having children with autosomal recessive and X-linked recessive disorders, to allow for informed decision making about reproductive options. The consequence may be a decrease in the birth prevalence of these conditions, which has occurred in several countries for some conditions. Different programs target different groups (high school, premarital, couples before conception, couples attending fertility clinics, and pregnant women) as does the governance structure (public health initiative and user pays).
    [Show full text]
  • Delivery of Treatment for Haemophilia
    WHO/HGN/WFH/ISTH/WG/02.6 ENGLISH ONLY Delivery of Treatment for Haemophilia Report of a Joint WHO/WFH/ISTH Meeting London, United Kingdom, 11 - 13 February 2002 Human Genetics Programme, 2002 Management of Noncommunicable Diseases World Health Organization Human Genetics Programme WHO/HGN/WFH/ISTH/WG/02.6 Management of Noncommunicable Diseases ENGLISH ONLY World Health Organization Delivery of Treatment for Haemophilia Report of a Joint WHO/WFH/ISTH Meeting London, United Kingdom, 11- 13 February 2002 Copyright ã WORLD HEALTH ORGANIZATION, 2002 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Gene Therapy: the Promise of a Permanent Cure
    INVITED COMMENTARY Gene Therapy: The Promise of a Permanent Cure Christopher D. Porada, Christopher Stem, Graça Almeida-Porada Gene therapy offers the possibility of a permanent cure for By providing a normal copy of the defective gene to the any of the more than 10,000 human diseases caused by a affected tissues, gene therapy would eliminate the problem defect in a single gene. Among these diseases, the hemo- of having to deliver the protein to the proper subcellular philias represent an ideal target, and studies in both animals locale, since the protein would be synthesized within the cell, and humans have provided evidence that a permanent cure utilizing the cell’s own translational and posttranslational for hemophilia is within reach. modification machinery. This would ensure that the protein arrives at the appropriate target site. In addition, although the gene defect is present within every cell of an affected ene therapy, which involves the transfer of a func- individual, in most cases transcription of a given gene and Gtional exogenous gene into the appropriate somatic synthesis of the resultant protein occurs in only selected cells of an organism, is a treatment that offers a precise cells within a limited number of organs. Therefore, only cells means of treating a number of inborn genetic diseases. that express the product of the gene in question would be Candidate diseases for treatment with gene therapy include affected by the genetic abnormality. This greatly simplifies the hemophilias; the hemoglobinopathies, such as sickle- the task of delivering the defective gene to the patient and cell disease and β-thalassemia; lysosomal storage diseases achieving therapeutic benefit, since the gene would only need and other diseases of metabolism, such as Gaucher disease, to be delivered to a limited number of sites within the body.
    [Show full text]
  • Guidelines for the Management of Haemophilia in Australia
    Guidelines for the management of haemophilia in Australia A joint project between Australian Haemophilia Centre Directors’ Organisation, and the National Blood Authority, Australia © Australian Haemophilia Centre Directors’ Organisation, 2016. With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Australia (http://creativecommons.org/licenses/by-nc-sa/3.0/au/) licence. You are free to copy, communicate and adapt the work for non-commercial purposes, as long as you attribute the authors and distribute any derivative work (i.e. new work based on this work) only under this licence. If you adapt this work in any way or include it in a collection, and publish, distribute or otherwise disseminate that adaptation or collection to the public, it should be attributed in the following way: This work is based on/includes the Australian Haemophilia Centre Directors’ Organisation’s Guidelines for the management of haemophilia in Australia, which is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Australia licence. Where this work is not modified or changed, it should be attributed in the following way: © Australian Haemophilia Centre Directors’ Organisation, 2016. ISBN: 978-09944061-6-3 (print) ISBN: 978-0-9944061-7-0 (electronic) For more information and to request permission to reproduce material: Australian Haemophilia Centre Directors’ Organisation 7 Dene Avenue Malvern East VIC 3145 Telephone: +61 3 9885 1777 Website: www.ahcdo.org.au Disclaimer This document is a general guide to appropriate practice, to be followed subject to the circumstances, clinician’s judgement and patient’s preferences in each individual case.
    [Show full text]
  • Bluebird Bio, Inc. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2019 bluebird bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35966 13-3680878 (State or Other Jurisdiction (IRS Employer of Incorporation) (Commission File Number) Identification No.) 60 Binney Street, Cambridge, MA 02142 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (339) 499-9300 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Title of each class Symbol(s) Name of each exchange on which registered Common Stock (Par Value $0.01) BLUE The NASDAQ Global Select Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    [Show full text]
  • Hemostasis: Definition
    Bleeding disorders in children prof. Mariusz Wysocki, Katedra i Klinika Pediatrii, Hematologii i Onkologii Collegium Medicum Bydgoszcz UMK Toruń Hemostasis: definition • the sum total of those specialized functions within the circulating blood and its vessels that are intended to stop hemorrhage Hemostasis: players and phases • plasma factors • Vascular phase • inhibitors • Platelet phase • fibrinolisis • Plasma phase • platelets • vessels The coagulation system Bleeding disorders: clinical approach • history • physical examination • laboratory tests Bleeding diosrders: signs and symptoms Site Within normal May be abnormal Usually due to a limits and due to a bleeding disorder number of causes Nose Finger – induced Unilateral Recurrent, requiring medical intervention or causing anemia Oral Blood on brush Gum ooze < 30 min Gum ooze > 30 min Gut Rectal fissure, blood Haematemesis, in nappy Melaena Bleeding diorders: signs and symptoms Site Within normal May be abnormal Usually due to a limits and due to a bleeding disorder number of causes Menstrual loss 4 – 7 days „same as Mum” Loss leading to anemia or transfusion Skin Shins don’t count Bony prominences Spontaneous bruising over soft areas, laceration bleeding > 30 min Joints and muscles Trauma induced Spontaneous Intracranial Neonatal , trauma Spontaneous induced History: neonates (Sharathkumar A, 2008, Bowman M, 2009) • prolonged bleeding at the circumcision site, • cephalohematomas, • prolonged umbilical stump bleeding Warning signgs and symptoms: Epistaxis: (Sharathkumar A, 2008,
    [Show full text]
  • Gene Therapy
    I Taylor GW, Edgar WI, Taylor BA, Neal DG. How safe is general practitioner obstetrics? Lancet than those in consultant units.22 The policy ofthe Department 1980;it: 1287-9. of Health, however, remains that recommended by the 2 Wood LAC. Obstetric retrospect. 7 R Coll Gen Pract 1981;31:80-90. 3 Klein M, Lloyd 1, Redman C, Bull M, Turnbull AC. A comparison of low-risk pregnant women Peel report,23 and repeated by the Short report in 198024: booked for delisery in two systems of care: shared-care (consultant, and integrated general facilities should be provided to permit hospital delivery in all practice unit. I. Obstetrical procedures and neonatal outcome. Br] Obstet Gvnaecol 1983;90: 118-22. cases. 4 Klein M, Lloyd 1, Redman C, Bull M, TIurnbull AC. A comparison of low-risk pregnant women This story of the happy pursuit of a policy unsupported by booked for delisery in two systems of care: shared-care (,consultant) and integrated general BMJ: first published as 10.1136/bmj.298.6675.691 on 18 March 1989. Downloaded from practice unit. II. Labour and delisery management and neonatal outcome. Br]7 Obstet Gvnaecol sound evidence is a sorry reflection on the political process. It 1983;90: 123-8. 5 Casenagh AJM, Phillips KM., Sheridan B, Williams EMJ. Contribution of isolated general has particular relevance now, when general practitioners have practitioner maternity units. BrMed] 1984;288:1438-40. been offered a contract obliging them to do yearly check ups 6 Shearer JML. Fise year prospectis-e survey of risk of booking for a home birth in Essex.
    [Show full text]
  • The Provision of Genetic Counselling Services for Haemophilia and Related Inherited Bleeding Conditions
    Clinical Genetics Services for Haemophilia This report on Clinical Genetic Services for Haemophilia has been compiled by the Genetics Working Party on behalf of the United Kingdom Haemophilia Centre Doctors’ Organisation. Review Date: May 2018 Contents Preface…………………………………………………………………………………………5 Executive Summary .................................................................................................................... 6 Membership of Working Party ................................................................................................... 8 Section 1. Introduction .............................................................................................................. 9 1.1 Genetic counselling ...................................................................................................... 9 1.2 Confidentiality and clinical records ........................................................................... 10 1.3 Information and Informed Consent ............................................................................ 10 1.4 Carriers of haemophilia .............................................................................................. 10 1.5 Genetic testing of children ......................................................................................... 10 1.6 UKHCDO Genetic Laboratory Network.................................................................... 10 1.7 Required resources ..................................................................................................... 11 1.8 Levels
    [Show full text]
  • Youth Perspectives on Genetic Inheritance, Carrier Status and Disclosure
    J Haem Pract 2016 3(2). doi:10.17225/jhp00077 CLINICAL REVIEW Youth perspectives on genetic inheritance, carrier status and disclosure Alpha-Umaru Barrie Knowledge about genetic inheritance as a concept in children and young people with bleeding disorders is synonymous, in many ways, with other inherited genetic conditions. Children and young people have a more physiological understanding of inheritance, but may hold mistaken and inaccurate beliefs in understanding basic genetics. There are complex ethical and social problems in the genetic testing of youngsters with bleeding disorders to establish carrier status. Current guideline recommendations indicate circumstances where clear psychosocial and medical benefits can be demonstrated. However, children and young people have a reduced capacity to understand the tests and their implications, and in many cases family communication may impact the extent of disclosure of genetic risk factors. This paper explores the genetics of inherited bleeding disorders, including basic knowledge of the concept of inheritance and reproductive risks. Carrier status in children and young people will be considered, drawing on legal rulings that may shed light on best practice in establishing carrier status based on genetic testing. Communication patterns within families around inherited bleeding disorders and the complicated process of disclosure will also be discussed. Keywords: inheritance, genetic risks, carrier, disclosure Inherited bleeding disorders comprise a varied series of conditions, including haemophilia A and B, von Willebrand disease (VWD), Glanzmann’s Thrombasthenia (GT), platelet function abnormalities and deficiencies in factor V, VII, X, XI and XIII. Most have their first clinical presentation in childhood [1]. All are characterised by a tendency to bleed excessively and a specific pattern of inheritance [2].
    [Show full text]
  • Detection of Point Mutations in the Dystrophin Gene
    Edith Cowan University Research Online Theses : Honours Theses 1993 Detection of point mutations in the dystrophin gene John Pedretti Edith Cowan University Follow this and additional works at: https://ro.ecu.edu.au/theses_hons Part of the Genetic Phenomena Commons, Genetics Commons, and the Genetic Structures Commons Recommended Citation Pedretti, J. (1993). Detection of point mutations in the dystrophin gene. https://ro.ecu.edu.au/ theses_hons/255 This Thesis is posted at Research Online. https://ro.ecu.edu.au/theses_hons/255 Edith Cowan University Copyright Warning You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorize you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following: Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. Where the reproduction of such material is done without attribution of authorship, with false attribution of authorship or the authorship is treated in a derogatory manner, this may be a breach of the author’s moral rights contained in Part IX of the Copyright Act 1968 (Cth). Courts have the power to impose a wide range of civil and criminal sanctions for infringement of copyright, infringement of moral rights and other offences under the Copyright Act 1968 (Cth). Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.
    [Show full text]
  • Heterogeneity of the Factor IX Locus in Nine Hemophilia B Inhibitor Patients
    Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients. R J Matthews, … , I R Peake, A L Bloom J Clin Invest. 1987;79(3):746-753. https://doi.org/10.1172/JCI112880. Research Article DNA from nine hemophilia B patients who produce anti-factor IX inhibitors (antibodies), including two brothers, was analyzed by the Southern blotting method and hybridization with factor IX cDNA, intragenomic, and 3'-flanking probes. Two inhibitor patients were shown to have total deletions of the factor IX gene. Two other inhibitor patients, the brothers, were shown to have a presumably identical complex rearrangement of the factor IX gene involving two separate deletions. The first deletion is of approximately 5.0 kb and removes exon e. The second deletion is between 9 and 29 kb and removes exons g and h but leaves exon f intact. An abnormal Taq I fragment at one end of the deletion junctions acted as a marker for the inheritance of hemophilia B in the patients' family. Five other inhibitor patients have a structurally intact factor IX gene as detected by this method. Our studies indicate that whereas large structural factor IX gene defects predispose hemophilia B patients to developing an anti-factor IX inhibitor, the development of an inhibitor can be associated with other defects of the factor IX gene. Find the latest version: https://jci.me/112880/pdf Heterogeneity of the Factor IX Locus in Nine Hemophilia B Inhibitor Patients R. James Matthews,* Don S. Anson,t Ian R. Peake,* and Arthur L. Bloom* *Department ofHematology, University of Wales College ofMedicine, Heath Park, Cardiff, Wales; and $Sir William Dunn School ofPathology, Oxford, United Kingdom Abstract and f.
    [Show full text]